Anti-human folate receptor beta antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-9914773-B2
Application number	US-201414524304-A
Country	US
Kind code	B2
Filing date	Oct 27, 2014
Priority date	Sep 9, 2010
Publication date	Mar 13, 2018
Grant date	Mar 13, 2018

Abstract

Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FRβ.

First claim

The invention claimed is:

1. An isolated human monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds human folate receptor beta (FRβ), the antibody or fragment comprising:
a heavy chain variable region (V H ) complementarity determining region (CDR) 1 comprising the amino acid sequence set forth in SEQ ID NO: 1;
a V H CDR2 comprising the amino acid sequence set forth in SEQ ID NO:2;
a V H CDR3 comprising the amino acid sequence set forth in SEQ ID NO:3;
a light chain variable region (V L ) CDR1 comprising the amino acid sequence set forth in SEQ ID NO:4;
a V L CDR2 comprising the amino acid sequence set forth in SEQ ID NO:5; and
a V L CDR3 comprising the amino acid sequence set forth in SEQ ID NO:6.

2. The antibody or fragment of claim 1 , wherein the antibody or fragment has one or more properties selected from the group consisting of:
(a) the antibody or fragment does not detectably bind to human folate receptor alpha (FRα);
(b) the antibody or fragment binds to human macrophages but not to mouse macrophages;
(c) the antibody or fragment has a binding affinity (EC 50 ) of 20 nM;
(d) the antibody or fragment has a dissociation constant (Kd) of 6.39 nM; and
(e) the antibody mediates antibody-dependent cellular cytotoxicity (ADCC) of FRβ-expressing target cells.

3. The antibody or fragment of claim 1 , wherein said antibody or fragment binds to cell surface FRβ.

4. The antibody or fragment of claim 1 , wherein said antibody is an IgG1 antibody.

5. The antibody or fragment of claim 1 , wherein said antibody or fragment is de-fucosylated.

6. The antibody or fragment of claim 1 , wherein the fragment is a Fab antibody fragment, a F(ab′) 2 fragment, or a single chain antibody fragment (scFv).

7. The antibody or fragment of claim 1 , conjugated with a pharmaceutical agent.

8. The antibody or fragment of claim 7 , wherein said pharmaceutical agent is a chemotherapeutic.

9. The antibody or fragment of claim 1 , conjugated to a liposome.

10. The antibody or fragment of claim 9 , wherein said liposome comprises a pharmaceutical agent.

11. The antibody or fragment of claim 1 , linked to a toxin.

12. The antibody or fragment of claim 11 , wherein said antibody or fragment thereof is covalently linked to said toxin.

13. The antibody or fragment of claim 1 , linked to a detectable moiety.

14. The antibody or fragment of claim 13 , wherein said detectable moiety is selected from the group consisting of a fluorescent moiety, a luminescent moiety, a radioactive moiety, a CT contrast agent, an MRI contrast agent, and biotin.

15. The antibody or fragment of claim 1 , wherein the antibody or fragment comprises one or more framework regions in SEQ ID NO: 7.

16. The antibody or fragment of claim 1 , wherein the antibody or fragment comprises SEQ ID NO: 10.

17. A composition comprising the antibody or fragment of claim 1 and a pharmaceutically acceptable carrier.

Assignees

• Purdue Research Foundation
• Us Health
• The United States Of America Depeartment Of Health And Human Services

Inventors

• Low Philip S
• Dimitrov Dimiter S
• Feng Yang
• Shen Jiayin

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title